Evidence map›Paper›PMID 36043494›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2022

Upregulation of p53 through induction of MDM2 degradation: improved potency through the introduction of an alkylketone sidechain on the anthraquinone core.

Ravi Tripathi, Abiodun Anifowose, Wen Lu, Xiaoxiao Yang, Binghe Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ravi TripathiDepartment of Chemistry, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.
Abiodun AnifowoseDepartment of Chemistry, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.
Wen LuDepartment of Chemistry, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.
Xiaoxiao YangDepartment of Chemistry, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.
Binghe WangDepartment of Chemistry, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.ORCID 0000-0002-2200-5270
Georgia State University · US

Funding

Novel anthraquinones induce apoptosis by disruption MDM2/MDM4 interactionsR01CA180519 · NCI · GEORGIA STATE UNIVERSITY · PI WANG, BINGHE, ZHOU, MUXIANG · 2014 to 2018
$2.2M
NCI NIH HHS R01 CA180519
6 · The paper itself

Abstract

Overexpression of ubiquitin ligase MDM2 causes depletion of the p53 tumour-suppressor and thus leads to cancer progression. In recent years, anthraquinone analogs have received significant attention due to their ability to downregulate MDM2, thereby promoting p53-induced apoptosis. Previously, we have developed potent anthraquinone compounds having the ability to upregulate p53

Indexed as

Proto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53AnimalsAnthraquinonesApoptosisUp-RegulationAnthraquinonesProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53anthraquinonecancerMDM2p53structure–activity relationship (SAR)

Identifiers

PMID36043494
PMCPMC9448394
OpenAlexW4293764756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.